Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 16 studies | 34% ± 13% | |
peripheral blood | 16 studies | 33% ± 9% | |
intestine | 10 studies | 27% ± 13% | |
kidney | 8 studies | 29% ± 9% | |
brain | 6 studies | 26% ± 8% | |
pancreas | 4 studies | 44% ± 16% | |
uterus | 4 studies | 36% ± 15% | |
lymph node | 4 studies | 33% ± 22% | |
breast | 4 studies | 31% ± 9% | |
liver | 4 studies | 25% ± 6% | |
bone marrow | 3 studies | 24% ± 7% | |
adrenal gland | 3 studies | 21% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 6974.69 | 258 / 258 | 100% | 152.93 | 230 / 230 |
brain | 100% | 5321.41 | 2642 / 2642 | 100% | 138.41 | 705 / 705 |
esophagus | 100% | 4235.93 | 1445 / 1445 | 100% | 70.30 | 183 / 183 |
kidney | 100% | 6265.69 | 89 / 89 | 100% | 160.42 | 901 / 901 |
liver | 100% | 3956.44 | 226 / 226 | 100% | 125.36 | 406 / 406 |
lung | 100% | 5440.93 | 578 / 578 | 100% | 122.35 | 1155 / 1155 |
ovary | 100% | 4230.48 | 180 / 180 | 100% | 136.77 | 430 / 430 |
pancreas | 100% | 3571.18 | 328 / 328 | 100% | 170.59 | 178 / 178 |
skin | 100% | 4437.40 | 1809 / 1809 | 100% | 143.30 | 472 / 472 |
thymus | 100% | 5119.72 | 653 / 653 | 100% | 180.33 | 605 / 605 |
uterus | 100% | 4201.34 | 170 / 170 | 100% | 140.73 | 459 / 459 |
prostate | 100% | 6091.68 | 245 / 245 | 100% | 177.89 | 501 / 502 |
stomach | 100% | 5257.03 | 359 / 359 | 100% | 108.88 | 285 / 286 |
intestine | 100% | 5157.39 | 966 / 966 | 100% | 130.63 | 525 / 527 |
bladder | 100% | 4609.71 | 21 / 21 | 100% | 156.50 | 502 / 504 |
breast | 100% | 5089.56 | 459 / 459 | 99% | 182.34 | 1111 / 1118 |
adipose | 100% | 4970.75 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 206.86 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 149.78 | 29 / 29 |
spleen | 100% | 5800.56 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 94.41 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 134.73 | 1 / 1 |
blood vessel | 100% | 4548.67 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 3102.05 | 860 / 861 | 0% | 0 | 0 / 0 |
muscle | 99% | 2278.39 | 791 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 2565.96 | 899 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006915 | Biological process | apoptotic process |
GO_0005886 | Cellular component | plasma membrane |
GO_0005515 | Molecular function | protein binding |
Gene name | TMEM219 |
Protein name | Transmembrane protein 219 Insulin-like growth factor-binding protein 3 receptor (IGFBP-3R) (Transmembrane protein 219) |
Synonyms | |
Description | FUNCTION: Cell death receptor specific for IGFBP3, may mediate caspase-8-dependent apoptosis upon ligand binding. . |
Accessions | Q86XT9 ENST00000414689.6 H3BML8 ENST00000279396.11 ENST00000575829.6 ENST00000569445.2 ENST00000561899.6 ENST00000566848.5 I3L2J7 ENST00000570255.6 ENST00000569481.1 I3L4B3 |